Topical infusion of metronidazole in the radiotherapy of tumours of the uterine cervix: interim report on the 2 year survival

1990

Closed access Metadata (CSL-JSON)
DOI 10.1259/0007-1285-63-750-499
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The negative outcome of many clinical radiotherapy trials seen after oral administration of hypoxic cell sensitizers in subtoxic doses can be attributed to an insufficient concentration of the drug in the neoplastic tissue (Brown, 1984). In a trial started in 1986 we sought to answer the question of whether the increased concentration in tumours expected after a direct, intratumoural administration of the sensitizer may improve the therapeutic effect of radiation treatment. Tumours of the uterine cervix were chosen for the trial, using metronidazole as the radiosensitizing substance. In a paper published recently (Balmukhanov et al, 1989), we reported some striking shortterm effects of radiotherapy combined with topical application of metronidazole. Thus, the local clearance rate, the decrease in tumour volume and the cytologic damage to tumours was greatly enhanced in the cases which received the combined treatment. Here we report the observations made during a 2 year follow-up period.